• Corpus ID: 33756730

KRN7000, a novel immunomodulator, and its antitumor activities.

@article{Kobayashi1995KRN7000AN,
  title={KRN7000, a novel immunomodulator, and its antitumor activities.},
  author={Eiichi Kobayashi and Kazuhiro Motoki and Takeshi Uchida and H. Fukushima and Y. Koezuka},
  journal={Oncology research},
  year={1995},
  volume={7 10-11},
  pages={
          529-34
        }
}
KRN7000, a compound with a novel alpha-galactosylceramide structure, showed potent tumor growth inhibitory activities in B16-bearing mice and markedly stimulated lymphocytic proliferation in allogeneic mixed leukocyte reaction, suggesting that KRN7000 is a biological response modifier. To confirm this suggestion, we examined the abilities of KRN7000 to enhance in vitro and in vivo natural killer (NK) activities, and found that KRN7000 enhanced in vitro and in vivo NK activities, and its potency… 
Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
TLDR
The results showed that the in vivo antitumor effects of KRN7000 on spontaneous liver metastases were dependent on the endogenous IL-12 production, where NKT cells in the liver are suggested to be involved.
A Pegylated Derivative of α-Galactosylceramide Exhibits Improved Biological Properties
TLDR
A pegylated derivative of αGalCerMPEG is characterized, which exhibits improved physical and biological properties and represents a promising tool for the development of immune interventions against infectious and non infected diseases.
Role of NKT cells and α-Galactosyl Ceramide
TLDR
KRN can prevent the onset of Type 1 Diabetes, inhibit replication of hepatitis virus B in liver and suppress malaria replication in activating NKT cells, and clinical study results in conjunction with DC and NKT cell activation are expected.
Clinical trials with α-galactosylceramide (KRN7000) in advanced cancer
TLDR
An overview of the preclinical data of α-GalCer that formed the basis for subsequent clinical trials in advanced cancer patients are provided, review these clinical trials, focusing on the own experience with α- GalCer, and discuss future perspectives.
α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
TLDR
It is demonstrated that NK1.1+αβTCR+ cell-based immune therapy can inhibit primary tumorigenesis and prevent tumor development in mouse models of chemical- and oncogene-dependent carcinogenesis.
Beta-Glucosylceramide Administration (i.p.) Activates Natural Killer T cells In Vivo and Prevents Tumor Metastasis in Mice
TLDR
It is demonstrated that β-GlcCer treatment activates invariant NKT cells, thus resulting in the inhibition of tumor metastasis, as well as increasing the cytotoxicity of hepatic lymphocytes against tumor cells.
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
  • G. Giaccone, C. Punt, H. Pinedo
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
KRN7000 is well tolerated in cancer patients over a wide range of doses and other therapeutic strategies aiming at reconstitution of the deficient NKT-cell population in cancer Patients may be warranted.
α-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3−CD56+ NK Cells In Vitro
TLDR
It is shown that α-glycosylceramides greatly enhance the cytotoxicity of human hepatic lymphocytes obtained from cancer patients against the tumor cell lines, K562 and Colo201, in vitro.
The stimulating adventure of KRN 7000.
TLDR
An up-to-date library of analogues is presented, collecting recent breakthroughs done in crystallography and molecular modelling, and relating them to the available biological results, in order to better understand the recognition and activation mechanisms of immune iNKT cells.
...
1
2
3
4
5
...